Proviral HIV-genome-wide and pol-gene specific Zinc Finger Nucleases: Usability for targeted HIV gene therapy
2011

Targeted HIV Gene Therapy Using Zinc Finger Nucleases

publication Evidence: moderate

Author Information

Author(s): Wayengera Misaki

Primary Institution: Makerere University

Hypothesis

Can zinc finger nucleases specifically disrupt HIV gene action to halt its replication?

Conclusion

Zinc finger nucleases may effectively disrupt HIV replication by excising a significant portion of proviral HIV DNA from infected cells.

Supporting Evidence

  • Zinc finger nucleases can specifically target and cleave HIV DNA sequences.
  • Lentiviral vectors are effective for delivering gene therapies to both dividing and non-dividing cells.
  • Preclinical models showed potential for these nucleases to disrupt HIV replication.

Takeaway

This study explores a new way to fight HIV by using special proteins that can cut the virus's DNA, potentially stopping it from making more copies of itself.

Methodology

The study involved computational generation of zinc finger arrays and nucleases, followed by modeling lentiviral vectors for gene delivery and testing in preclinical models.

Potential Biases

The study may be biased towards the efficacy of zinc finger nucleases without extensive clinical validation.

Limitations

Potential genome toxicity and limited clinical trials of lentiviral vectors may hinder the technology's application in humans.

Digital Object Identifier (DOI)

10.1186/1742-4682-8-26

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication